Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Unicancer

Enrolment target

1,080

Start

21 Jul 2023

The primary endpoint is the progression free survival (PFS).

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.